Lumos Pharma (NASDAQ:LUMO) Given “Buy” Rating at HC Wainwright

Lumos Pharma (NASDAQ:LUMO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $28.00 price objective on the stock.

Several other research analysts have also commented on LUMO. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a report on Tuesday. Oppenheimer reduced their target price on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd.

Lumos Pharma Trading Down 1.6 %

Shares of LUMO traded down $0.06 during mid-day trading on Friday, reaching $3.78. The company had a trading volume of 3,789 shares, compared to its average volume of 43,459. The stock has a market cap of $30.69 million, a price-to-earnings ratio of -0.82 and a beta of 0.78. The firm has a fifty day simple moving average of $2.98 and a 200-day simple moving average of $2.68. Lumos Pharma has a fifty-two week low of $1.37 and a fifty-two week high of $4.55.

Lumos Pharma (NASDAQ:LUMO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.33. The firm had revenue of $0.49 million during the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same period last year, the firm posted ($1.09) EPS. As a group, equities analysts predict that Lumos Pharma will post -2.56 EPS for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.